Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02952001 · ClinicalTrials.gov registry record
MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301
A clinical trial of Uveitis and Uveitis, Posterior, sponsored by Clearside Biomedical.
- Completed
- Registry status
- 33
- Enrollment target
- 16
- Study locations
NCT02952001: Completed study of Uveitis and Uveitis, Posterior, sponsored by Clearside Biomedical.
NCT02952001 is a study of Uveitis and Uveitis, Posterior that has completed, run by Clearside Biomedical. The registered enrollment target is 33 participants, below the 616-participant average among 19 other Uveitis trials with a reported enrollment target (95% lower). The trial reports 16 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02952001, a study of Uveitis and Uveitis, Posterior, has completed, sponsored by Clearside Biomedical.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
- 16
- Study locations
Study Summary
This study is a non-interventional, observational extension of the Parent study, CLS1001-301 (NCT02595398). The purpose of this study is to characterize the continued clinical benefit(s) regarding safety and efficacy of suprachoroidally administered CLS-TA, triamcinolone acetonide injectable suspension, for the treatment of macular edema associated with non-infectious uveitis.
Primary Outcome
This time to event outcome was calculated as the number of days between the date of initiation of additional therapy for uveitis and the date of first treatment in the Parent study CLS1001-301 (NCT02595398).
Conditions Studied
Interventions
- DRUG Sham procedure
- DRUG 4 mg CLS-TA Suprachoriodal Injection
Study Locations (16)
Texas
- Texas Retina Associates - Dallas
- Retina Consultants of Houston - The Woodlands
Other
- Disha Eye Hospitals Pvt. Ltd. - Kolkata
- Dr Rajendra Prasad Centre for Ophthalmic Sciences - New Delhi
Arizona
- Retinal Consultants of Arizona - Phoenix
California
- Northern California Retina Vitreous Associates Medical Group, Inc. - Mountain View
Florida
- Retina Group of Florida - Fort Lauderdale
Georgia
- Marietta Eye Clinic - Marietta
Massachusetts
- Valley Eye Physicians and Surgeons, PC - Ayer
North Dakota
- Bergstrom Eye Research - Fargo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2017-12-13 |
| Est. Completion | 2018-05-22 |
What the finished NCT02952001 record still lists
NCT02952001 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 616-participant average among 19 other Uveitis trials with a reported enrollment target (95% lower).
The record links to 5 conditions, with Uveitis appearing as the primary indexed condition, and to 2 interventions - of which Sham procedure is the first listed.
NCT02952001 lists 16 locations in 14 states (Texas, Other, Arizona).
Frequently Asked Questions
What is clinical trial NCT02952001 about?
NCT02952001 is a clinical study titled "MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301". This study is a non-interventional, observational extension of the Parent study, CLS1001-301 (NCT02595398). The purpose of this study is to characterize the continued clinical benefit(s) regarding safety and efficacy of suprachoroidally administered CLS-TA, triamcinolone acetonide injectable suspens...
What is the current status of trial NCT02952001?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2017-12-13. Estimated completion is 2018-05-22.
What conditions does trial NCT02952001 study?
This clinical trial studies the following conditions: Uveitis, Uveitis, Posterior, Uveitis, Intermediate, Uveitis, Anterior, Panuveitis.
What interventions are being tested in trial NCT02952001?
The interventions under investigation include: Sham procedure (DRUG), 4 mg CLS-TA Suprachoriodal Injection (DRUG).
Who is sponsoring clinical trial NCT02952001?
This trial is sponsored by Clearside Biomedical, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02952001 being conducted?
This trial has 16 study locations across Arizona, California, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02952001's enrollment target sits among peer trials
33 15th of 19 higher than 5 of 19 other Uveitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Uveitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric Age
RECRUITING
-
Genetics of Uveitis
RECRUITING
-
Analysis of Anterior Chamber Inflammation by Optical Coherence Tomography
RECRUITING
-
Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing
RECRUITING · NA
-
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
RECRUITING · Phase 3
-
Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI